1,2,4-Trichlorobenzene (as the metabolite 2,4,5-trichlorophenol)  
**Organophosphate Pesticides**  
Chlorpyrifos (as the metabolite 3,5,6-trichloro-2-pyridinol)  
Phenols  
ortho-Phenylphenol  
N-Methyl Carbamates  
Carbaryl (as the metabolite 1-naphthol)  
Carbofuran (as the metabolite carbofuranphenol)  
Propoxur (as the metabolite 2-isopropoxyphenyl)  
Alachlor (as the metabolite alachlor mercapturate)  
Triazines  
Atrazine (as the metabolite atrazine mercapturate)  
Other Herbicides  
2,4-Dichlorophenoxyacetic acid (2,4-D)  
Polychlorinated Biphenyls (PCBs)  
PCB numbers 52, 66, 81, 99, 101, 105, 118, 126, 128, 136, 146, 153, 156, 157, 167, 169, 170, 180, and 183  
Nominated Chemicals or Chemical Categories Already Planned for Inclusion in Future “Reports”  
Metals  
Arsenic (speciated and total)  
Methyl mercury  
**Volatile Organic Compounds (VOCs)**  
Benzene  
1,1,1-Trichloroethane  
1,2-Dichlorobenzene  
Carbon tetrachloride  
Chloroform  
Toluene  
Xylenes (o, m, p-isomers)  
**Polybrominated Compounds**  
Polychlorinated biphenyls (PCBs)  
Polychlorinated diphenyl ethers (PCDEs)  
Tetrabromodiphenyl ether (TBDE)  
Pentabromodiphenyl ether (PBDE)  
Heptabromodiphenyl ether (PBDE)  
Decabromodiphenyl ether (DBDE)  
Hexabromocyclododecane (HBCD)  
Tetrabromobisphenol A (TBBP-A)  
**Organochlorine Pesticides**  
alpha Hexachlorocyclohexane (HCH)  
Aldrin (as the metabolite endrin)  
4,4′-DDD (p,p′-DDD; DDD)  
Dieldrin  
Endosulfan  
Endrin  
Methoxychlor  
Octachlorostyrene  
Pentachlorobenzene (as the metabolite pentachlorophenol)  
Toxaphene  
**Chloroacetanilides**  
Atrazine (as the metabolite atrazine mercapturate)  
Methoxychlor  
Aldrin (as the metabolite endrin)  
Octochlorostyrene  
Methamidophos  
Coumaphos (also as dialkyl phosphate metabolites)  
Chlorpyrifos (as the metabolite 3,5,6-trichloro-2-pyridinol)  
**Perfluorinated Compounds**  
Perfluorooctanoic acid (PFOA), including metabolites  
Perfluorohexanoic sulfonic acid (PFHxS)  
**Polyaromatic Hydrocarbons**  
Benzo(a)anthracene  
Benzo(a)pyrene  
Benzo(b)fluoranthene  
Benzo(k)fluoranthene  
Benzo(g,h,i)perfluorine  
Carbazole  
Benzo(a)pyrene  
Benzo(b)fluoranthene  
Benzo(k)fluoranthene  
Benzo(g,h,i)perfluorine  
Carbazole  
**Organochlorine Pesticides**  
Acephate  
Azinphos-methyl (also as dialkyl phosphate metabolites)  
Coumaphos (also as dialkyl phosphate metabolites)  
Methamidophos  
**Organophosphate Pesticides**  
Acephate  
Azinphos-methyl (also as dialkyl phosphate metabolites)  
Coumaphos (also as dialkyl phosphate metabolites)  
Methamidophos  
**Polychlorinated Biphenyls (PCBs)**  
PCB numbers 77, 87, 151, 158, 189, 194, 195, 169, 203, 206, and 209  
**SUPPLEMENTARY INFORMATION:** CDC publishes the “Report” under the authorities 42 U.S.C. 241 and 42 U.S.C. 242k. The “Report” provides an ongoing assessment using biomonitoring of the exposure of the noninstitutionalized, U.S. civilian population to environmental chemicals. Biomonitoring assesses human exposure to chemicals by measuring the chemicals or their breakdown products in human specimens such as blood or urine. For the “Report,” an environmental chemical means a chemical compound or chemical element present in air, water, soil, dust, food, or other environmental medium. The “Report” provides exposure information about participants in an ongoing national survey known as the National Health and Nutrition Examination Survey (NHANES). This survey is conducted by CDC’s National Center for Health Statistics; biomonitoring measurements are conducted by CDC’s National Center for Environmental Health. The first “Report,” published in March 2001, gave information about levels of 27 chemicals in the U.S. population. The second “Report,” published in January 2003, provided data on 116 chemicals, including expanded data on the 27 in the first “Report,” and was the most extensive assessment ever of the exposure of the U.S. population to environmental chemicals. The “Report” can be obtained in the following ways: Access http://www.cdc.gov/exposurereport; e-mail ncehdis@cdc.gov; or telephone 1–866–670–6052.

Current plans are to release future reports of exposure of the U.S. population that cover 2-year periods (e.g., 2001–2002; 2003–2004; 2005–2006) and that will include data on more chemicals than the 116 listed in the second “Report.” Over time, CDC will be able to track trends in exposure levels. Future releases also may include additional exposure information for special exposure populations (e.g., children, women of childbearing age, elderly people) from studies examining localized or point sources and from studies of adverse health effects resulting from exposure to varying levels of environmental chemicals.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.


Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 03–24671 Filed 9–29–03; 8:45 am]

BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 2000N–1530]

Richard L. Borison; Debarment Order

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) debarring Dr. Richard L. Borison for 10 years from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Dr. Borison was convicted of felonies under Georgia State law for racketeering, theft, and false statements and representations,
and was a material participant in offenses for which another person is being debarred. Dr. Borison has failed to request a hearing and, therefore, has waived his opportunity for a hearing concerning this action.

DATES: This order is effective September 30, 2003.

ADDRESSES: Submit applications for termination of debarment to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm., 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Mary Catchings, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

On October 8, 1998, the Superior Court for the County of Richmond, State of Georgia, accepted Dr. Borison’s plea of guilty and entered judgment against him for 36 counts of criminal offenses under Georgia State law for racketeering, theft, and false statements and representations.

As a result of this conviction, FDA served Dr. Borison by certified mail on December 5, 2002, a notice proposing to debar him for 10 years from providing services in any capacity to a person that has an approved or pending drug product application. The proposal also offered Dr. Borison an opportunity for a hearing on the proposal. The debarment proposal was based on findings: (1) Under section 306(b)(2)(B)(ii) of the act (21 U.S.C. 335a(b)(2)(B)(ii)) that Dr. Borison was convicted of felonies under State law for racketeering, theft, and false statements and representations; and (2) under section 306(b)(2)(B)(iii) of the act that Dr. Borison was a material participant in offenses leading to the conviction and debarment of another individual. Dr. Borison was provided 30 days to file objections and to request a hearing. His failure to request a hearing constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment.

II. Findings and Order

The Department of Health and Human Services (HHS) has determined, based on findings: (1) Has been convicted of a felony under State law for racketeering, theft, and false statements and representations; and (2) was a material participant in offenses leading to the conviction of another individual.

As a result of the foregoing findings, Dr. Richard L. Borison is debarred for 10 years (two periods of 5 years, to run consecutively, based on his conviction for State felonies and his role as a material participant in the offenses leading to the conviction and debarment of another individual) from providing services in any capacity to a person that has an approved or pending drug product application under section 505, 512, or 502 of the act (21 U.S.C. 355, 360b, or 382) or under section 351 of the Public Health Service Act (42 U.S.C. 262)(see sections 306(c)(1)(B) and (c)(2)(A)(iii) and 201(dd) of the act (21 U.S.C. 321(dd))). Any person with an approved or pending drug product application who knowingly uses the services of Dr. Borison in any capacity during his period of debarment will be subject to civil money penalties. If Dr. Borison, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties. In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Dr. Borison during his period of debarment.

Any application by Dr. Borison for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 2000N–1530 and sent to the Division of Dockets Management (see ADDRESSES). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.


Janet Woodcock,
Director, Center for Drug Evaluation and Research.

[FR Doc. 03–24656 Filed 9–29–03; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 2000N–1428]

Suhas V. Sardesai; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Suhas V. Sardesai from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Sardesai was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Sardesai failed to request a hearing and, therefore, has waived his opportunity for a hearing concerning this action.

DATES: This order is effective September 30, 2003.

ADDRESSES: Submit applications for termination of debarment to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Mary Catchings, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

On October 28, 1998, the U.S. District Court for the District of Maryland accepted Mr. Suhas V. Sardesai’s plea of guilty to one count of distributing an adulterated drug into interstate commerce, a Federal felony offense under section 301(a)(2)(B) of the act (21 U.S.C. 351(a)(2)(B)).

As a result of this conviction, FDA served Mr. Sardesai by certified mail on July 24, 2002, a notice proposing to permanently debar him from providing services in any capacity to a person that has an approved or pending drug product application. The proposal also offered Mr. Sardesai an opportunity for a hearing on the proposal. The proposal was based on a finding, under section 306(a)(2)(B) of the act (21 U.S.C. 335a(a)(2)(B)), that Mr. Sardesai was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Sardesai was provided 30 days to file objections and request a hearing. Mr. Sardesai did not request a hearing. His failure to request a hearing constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment.

II. Findings and Order

Therefore, the Director, Center for Drug Evaluation and Research, under section 306(b)(2)(B) of the act, and under authority delegated to her (21 CFR 5.34), finds that Mr. Richard L. Borison: (1) Has been convicted of a felony under State law for racketeering, theft, and false statements and representations; and (2) was a material participant in offenses leading to the conviction of another individual.

As a result of the foregoing findings, Dr. Richard L. Borison is debarred for 10 years (two periods of 5 years, to run consecutively, based on his conviction for State felonies and his role as a material participant in the offenses leading to the conviction and debarment of another individual) from providing services in any capacity to a person that has an approved or pending drug product application under section 505, 512, or 502 of the act (21 U.S.C. 355, 360b, or 382) or under section 351 of the Public Health Service Act (42 U.S.C. 262)(see sections 306(c)(1)(B) and (c)(2)(A)(iii) and 201(dd) of the act (21 U.S.C. 321(dd))). Any person with an approved or pending drug product application who knowingly uses the services of Dr. Borison in any capacity during his period of debarment will be subject to civil money penalties. If Dr. Borison, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties. In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Dr. Borison during his period of debarment.

Any application by Dr. Borison for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 2000N–1530 and sent to the Division of Dockets Management (see ADDRESSES). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.


Janet Woodcock,
Director, Center for Drug Evaluation and Research.

[FR Doc. 03–24656 Filed 9–29–03; 8:45 am]